In GBM and chondrosarcoma—tumors with historically poor responsiveness to conventional chemotherapy—such ALT-specific vulnerabilities may help explain why ALT-positive patients exhibit relatively better survival when compared with ALT-negative cases [8,40,41,49,50]. This evidence concerns the gene GPT and chondrosarcoma.